GRCE
Grace Therapeutics, Inc.
NASDAQ: GRCE · HEALTHCARE · BIOTECHNOLOGY
$2.10
+0.00% today
Updated 2026-04-29
Market cap
$33.42M
P/E ratio
—
P/S ratio
197.75x
EPS (TTM)
$-0.31
Dividend yield
—
52W range
$2 – $5
Volume
0.8M
Grace Therapeutics, Inc. (GRCE) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-10.20%
ROA
-10.80%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2010 | — | $-1.51M | — | — | — |
| 2011 | $29040.00 | $-3.08M | 100.00% | -10,980.25% | -10,592.29% |
| 2012 | $10475.00 | $-6.54M | 51.25% | -62,535.93% | -62,421.58% |
| 2013 | $707395.00 | $-6.73M | 43.89% | -963.82% | -951.66% |
| 2014 | $450159.00 | $-10.44M | 41.73% | -2,156.13% | -2,318.29% |
| 2015 | $216288.00 | $-1.32M | 13.13% | -4,580.47% | -611.68% |
| 2016 | $27787.00 | $-4.66M | -116.22% | -25,526.33% | -16,777.63% |
| 2018 | — | $-16.65M | — | — | — |
| 2019 | — | $-39.37M | — | — | — |
| 2020 | — | $-25.51M | — | — | — |
| 2021 | $196000.00 | $-19.68M | 61.22% | -8,377.04% | -10,039.80% |
| 2022 | $0.00 | $-9.82M | — | — | — |
| 2023 | $0.00 | $-42.43M | — | — | — |
| 2024 | $0.00 | $-12.85M | — | — | — |
| 2025 | $0.00 | $-9.57M | — | — | — |